Home › Funds › PFM Health Sciences, LP › TNGX
PFM Health Sciences, LP position in TNGX
TANGO THERAPEUTICS INC · Health Care
PFM Health Sciences, LP reported holding 326,047 shares of TNGX (TANGO THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$10.2M, representing 0.89% of its reported portfolio and ranking #41 among its reported holdings. PFM Health Sciences, LP has disclosed TNGX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How PFM Health Sciences, LP's TNGX position evolved
PFM Health Sciences, LP first disclosed a stake in TNGX in Q1 2026 at 406,245 shares (US$8.5M). The position peaked in Q2 2026 at 326,047 shares, worth US$10.2M. Across 2 filings, PFM Health Sciences, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 326,047 shares valued at US$10.2M — a reduction of -80,198 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 406.25K | $8.50M | New |
| Q2 2026 | 326.05K | $10.19M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TNGX and 13F data
TNGX (TANGO THERAPEUTICS INC) is a Health Care company. 84 other funds we track also report a position in TNGX — the largest reported positions include RTW INVESTMENTS, LP (US$434.5M), Farallon Capital Management (US$383.8M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$383.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TNGX
- RTW INVESTMENTS, LP 13.90M sh · $434.53M · Q2 2026
- Farallon Capital Management 12.28M sh · $383.78M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 12.28M sh · $383.78M · Q2 2026
- Boxer Capital Management, LLC 10.88M sh · $339.99M · Q2 2026
- TCG Crossover Management, LLC 9.08M sh · $283.88M · Q2 2026
- Paradigm Biocapital Advisors LP 6.36M sh · $198.74M · Q2 2026
- Siren, L.L.C. 6.18M sh · $193.17M · Q2 2026
- Deep Track Capital, LP 4.20M sh · $131.29M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.19M sh · $131.00M · Q2 2026
- Woodline Partners LP 4.00M sh · $125.06M · Q2 2026
- TRV GP IV, LLC 6.37M sh · $120.18M · Q2 2026
- PERCEPTIVE ADVISORS LLC 3.38M sh · $105.57M · Q2 2026
More on PFM Health Sciences, LP
FAQ
How long has PFM Health Sciences, LP held TNGX?
PFM Health Sciences, LP has disclosed TNGX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is PFM Health Sciences, LP's current position in TNGX?
As of Q2 2026, PFM Health Sciences, LP holds 326.05K shares of TNGX (TANGO THERAPEUTICS INC), valued at $10.19M, representing 0.89% of its reported portfolio and ranking #41.
Has PFM Health Sciences, LP been buying or selling TNGX?
In the latest 13F filing (Q2 2026), PFM Health Sciences, LP reduced its position in TNGX. The position peaked in Q2 2026 at 326.05K shares.
Which other funds hold TNGX?
Other major institutional holders of TNGX include RTW INVESTMENTS, LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 84 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.